KR101376807B1 - 스티릴피리딘 유도체 및 그의 아밀로이드 플라크에 결합 및영상화를 위한 용도 - Google Patents

스티릴피리딘 유도체 및 그의 아밀로이드 플라크에 결합 및영상화를 위한 용도 Download PDF

Info

Publication number
KR101376807B1
KR101376807B1 KR1020087023884A KR20087023884A KR101376807B1 KR 101376807 B1 KR101376807 B1 KR 101376807B1 KR 1020087023884 A KR1020087023884 A KR 1020087023884A KR 20087023884 A KR20087023884 A KR 20087023884A KR 101376807 B1 KR101376807 B1 KR 101376807B1
Authority
KR
South Korea
Prior art keywords
compound
alkyl
compounds
delete delete
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020087023884A
Other languages
English (en)
Korean (ko)
Other versions
KR20080106564A (ko
Inventor
행크. 에프. 쿵
메이-핑 쿵
Original Assignee
더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 filed Critical 더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Publication of KR20080106564A publication Critical patent/KR20080106564A/ko
Application granted granted Critical
Publication of KR101376807B1 publication Critical patent/KR101376807B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020087023884A 2006-03-30 2008-09-29 스티릴피리딘 유도체 및 그의 아밀로이드 플라크에 결합 및영상화를 위한 용도 Active KR101376807B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78715606P 2006-03-30 2006-03-30
US60/787,156 2006-03-30
PCT/US2007/007400 WO2007126733A2 (en) 2006-03-30 2007-03-26 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques

Publications (2)

Publication Number Publication Date
KR20080106564A KR20080106564A (ko) 2008-12-08
KR101376807B1 true KR101376807B1 (ko) 2014-03-20

Family

ID=38326579

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087023884A Active KR101376807B1 (ko) 2006-03-30 2008-09-29 스티릴피리딘 유도체 및 그의 아밀로이드 플라크에 결합 및영상화를 위한 용도

Country Status (35)

Country Link
US (3) US7687052B2 (enExample)
EP (3) EP2363391A1 (enExample)
JP (1) JP5290954B2 (enExample)
KR (1) KR101376807B1 (enExample)
CN (1) CN101522624B (enExample)
AT (1) ATE539060T1 (enExample)
AU (1) AU2007243712B2 (enExample)
BE (1) BE2013C044I2 (enExample)
BR (1) BRPI0710225B1 (enExample)
CA (1) CA2644530C (enExample)
CR (1) CR10329A (enExample)
CY (3) CY1113048T1 (enExample)
DK (2) DK1999109T3 (enExample)
EA (1) EA017898B1 (enExample)
EC (1) ECSP088783A (enExample)
ES (2) ES2378785T3 (enExample)
FR (1) FR13C0034I2 (enExample)
GT (1) GT200800201A (enExample)
HR (2) HRP20120135T1 (enExample)
HU (2) HUE032660T2 (enExample)
IL (1) IL193567A (enExample)
LT (1) LT2363392T (enExample)
LU (1) LU92232I2 (enExample)
MX (1) MX2008012527A (enExample)
NO (2) NO342090B1 (enExample)
NZ (1) NZ570887A (enExample)
PL (2) PL1999109T3 (enExample)
PT (2) PT1999109E (enExample)
RS (2) RS56171B1 (enExample)
SG (1) SG173338A1 (enExample)
SI (2) SI2363392T1 (enExample)
TW (1) TWI399366B (enExample)
UA (1) UA97802C2 (enExample)
WO (1) WO2007126733A2 (enExample)
ZA (1) ZA200807955B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1999109T3 (pl) * 2006-03-30 2012-05-31 Univ Pennsylvania Pochodne styrylopirydyny i ich zastosowanie do wiązania i obrazowania blaszek amyloidowych
EP2172444A4 (en) * 2007-07-04 2010-12-22 Univ Tohoku PET PROBE WITH FLUORO-SUBSTITUTED ALKOXY GROUP AND HYDROXYGRUPPE
JP5603855B2 (ja) * 2008-04-04 2014-10-08 アビッド レディオファーマシューティカルズ、インク． 神経変成疾患の放射性薬剤による画像化
PT2381967T (pt) * 2008-12-31 2017-02-24 Avid Radiopharmaceuticals Inc Síntese de estirilpiridinas radiomarcadas com 18f a partir de precursores tosilato e as suas composições farmacêuticas estáveis
CA2767475A1 (en) * 2009-07-10 2011-01-13 Bayer Pharma Aktiengesellschaft Usage of low to medium-pressure liquid chromatography for the purification of radiotracers
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
MX336896B (es) * 2009-12-23 2016-02-05 Piramal Imaging Sa Formulaciones adecuadas para la generacion de imagenes pet con agentes pet hidrofobicos.
WO2011141515A1 (en) 2010-05-14 2011-11-17 Bayer Pharma Aktiengesellschaft Diagnostic agents for amyloid beta imaging
CA2801525A1 (en) * 2010-06-04 2011-12-08 Piramal Imaging Sa Method for production of f-18 labeled amyloid beta ligands
TWI504414B (zh) 2010-06-04 2015-10-21 Bayer Schering Pharma Ag 生產Ｆ－１８標記之Ａβ配位體之方法
SG185782A1 (en) 2010-06-04 2013-01-30 Piramal Imaging Sa Method for production of f-18 labeled amyloid beta ligands
WO2011151282A1 (en) * 2010-06-04 2011-12-08 Bayer Pharma Aktiengesellschaft Method for production of f-18 labeled amyloid beta ligand
CN101891674B (zh) * 2010-06-24 2012-11-14 山东大学 4-苯乙烯基吡啶类化合物及其制备方法与应用
EP2627361B1 (en) * 2010-10-12 2017-09-20 Mayo Foundation For Medical Education And Research Imaging of meningiomas using phenylbenzothiazole, stilbene, or biphenylalkyne derivatives
US20140079635A1 (en) * 2011-03-30 2014-03-20 Case Western Reserve University Molecular probes for detecting lipid composition
EP2699157B1 (en) 2011-04-21 2018-03-14 The Regents of The University of California Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles
EP2768790A1 (en) 2011-10-19 2014-08-27 Piramal Imaging SA IMPROVED METHOD FOR PRODUCTION OF F-18 LABELED Aß LIGANDS
PT2836241T (pt) 2012-04-10 2019-05-30 Lantheus Medical Imaging Inc Métodos de síntese de radiofármacos
JP6099045B2 (ja) * 2013-04-30 2017-03-22 国立大学法人京都大学 トリアゾロピリミジン誘導体化合物
JP6041751B2 (ja) * 2013-05-07 2016-12-14 日本メジフィジックス株式会社 スチリルピリジン誘導体化合物
JP2014218454A (ja) * 2013-05-07 2014-11-20 日本メジフィジックス株式会社 スチリルピリジン誘導体化合物
CN103645254B (zh) * 2013-11-28 2015-01-07 江苏省原子医学研究所 一种Aβ斑块显像剂前体AV45的含量分析方法
HUE053939T2 (hu) 2014-05-13 2021-08-30 Hoffmann La Roche Deuterált heterociklikus vegyületek és képalkotó kontrasztanyagként való használatuk
CA2994178C (en) 2015-08-18 2024-03-19 The Regents Of The University Of California Nitroxide containing amyloid binding agents for imaging and therapeutic uses
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
CN109400615B (zh) * 2017-08-18 2021-07-16 上海交通大学医学院附属新华医院 一种靶向β-淀粉样蛋白的香豆素类化合物及其制备与应用
CN108299287A (zh) * 2018-01-02 2018-07-20 北京师范大学 与Aβ斑块具有高亲和力的N2S2类吡啶基苯乙烯化合物
CN114805190A (zh) * 2022-06-08 2022-07-29 吉林大学第一医院 一种甲基苯胺类Aβ蛋白显像剂的双柱合成方法
WO2024107620A1 (en) 2022-11-14 2024-05-23 Eli Lilly And Company Polymorphic forms of florbetapir precursor av-105

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000963A1 (fr) * 1990-07-12 1992-01-23 Yoshitomi Pharmaceutical Industries, Ltd. Composes de styryle et leur utilisation comme medicaments
JPH0545875A (ja) * 1991-08-08 1993-02-26 Konica Corp 感光性組成物
US6020436A (en) * 1993-03-09 2000-02-01 The Chromaline Corporation Photosensitive resin composition
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
AU2001239544A1 (en) * 2000-03-22 2001-10-03 Bf Research Institute, Inc. Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same
US8007954B2 (en) 2000-11-09 2011-08-30 The Trustees Of The University Of Pennsylvania Use of sulfur-containing fuels for direct oxidation fuel cells
JP2002182254A (ja) 2000-12-18 2002-06-26 Fuji Photo Film Co Ltd 非線形光学材料とその製造方法
CN1299777C (zh) * 2001-08-27 2007-02-14 宾夕法尼亚州大学理事会 茋衍生物及其用于结合和成像淀粉样蛋白斑的用途
JP2005529464A (ja) 2002-06-06 2005-09-29 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア セラミックアノード及びそれを生産する方法
WO2004016271A1 (en) * 2002-08-14 2004-02-26 Axxima Pharmaceuticals Ag Pyrimidones as antiviral agents
JP4482352B2 (ja) 2004-03-11 2010-06-16 本田技研工業株式会社 固体高分子型燃料電池
EP2213652B1 (en) * 2004-12-17 2014-10-22 The Trustees of The University of Pennsylvania Stilbene derivatives and their use for binding and imaging amyloid plaques
US7858072B2 (en) * 2004-12-17 2010-12-28 The Trustees Of The University Of Pennsylvania Stilbene derivatives and their use for binding and imaging amyloid plaques
JP2008546804A (ja) * 2005-06-24 2008-12-25 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 造影剤として用いるためのリガンドの放射性標識ペグ化
PL1999109T3 (pl) * 2006-03-30 2012-05-31 Univ Pennsylvania Pochodne styrylopirydyny i ich zastosowanie do wiązania i obrazowania blaszek amyloidowych
US20080253967A1 (en) * 2007-04-13 2008-10-16 Kung Hank F Halo-Stilbene Derivatives And Their Use For Binding And Imaging Of Amyloid Plaques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nuclear Medicine and Biology, 32(4), pp 329~335(2005)

Also Published As

Publication number Publication date
MX2008012527A (es) 2008-10-14
CN101522624A (zh) 2009-09-02
NO2018030I1 (no) 2018-09-11
EP2363392A1 (en) 2011-09-07
WO2007126733A2 (en) 2007-11-08
US20080038195A1 (en) 2008-02-14
KR20080106564A (ko) 2008-12-08
NO342090B1 (no) 2018-03-19
BRPI0710225B1 (pt) 2021-07-13
EA017898B1 (ru) 2013-04-30
JP5290954B2 (ja) 2013-09-18
PT1999109E (pt) 2012-03-16
UA97802C2 (uk) 2012-03-26
NZ570887A (en) 2011-05-27
ATE539060T1 (de) 2012-01-15
EP1999109A2 (en) 2008-12-10
FR13C0034I1 (enExample) 2013-08-09
HUE032660T2 (en) 2017-10-30
CY1113048T1 (el) 2015-11-04
US8506929B2 (en) 2013-08-13
ES2628882T3 (es) 2017-08-04
IL193567A0 (en) 2009-05-04
NO20084590L (no) 2008-12-29
IL193567A (en) 2014-03-31
WO2007126733A3 (en) 2008-03-06
CY2013024I1 (el) 2015-11-04
CA2644530C (en) 2015-05-19
DK1999109T3 (da) 2012-04-02
BRPI0710225A2 (pt) 2011-08-02
EP2363391A1 (en) 2011-09-07
CR10329A (es) 2008-10-29
LU92232I2 (fr) 2013-08-26
US20130129624A1 (en) 2013-05-23
AU2007243712A1 (en) 2007-11-08
EP2363392B1 (en) 2017-05-03
US7687052B2 (en) 2010-03-30
BE2013C044I2 (enExample) 2026-04-24
RS56171B1 (sr) 2017-11-30
CN101522624B (zh) 2013-11-06
JP2009532349A (ja) 2009-09-10
RS52222B (sr) 2012-10-31
LU92232I9 (enExample) 2019-01-15
HRP20120135T1 (hr) 2012-03-31
SI2363392T1 (sl) 2017-09-29
ZA200807955B (en) 2012-11-28
PL2363392T3 (pl) 2017-10-31
HRP20170857T1 (hr) 2017-12-01
ECSP088783A (es) 2008-10-31
EP1999109B1 (en) 2011-12-28
HUS1300028I1 (hu) 2017-08-28
US20090123369A1 (en) 2009-05-14
TWI399366B (zh) 2013-06-21
TW200838852A (en) 2008-10-01
CY1119048T1 (el) 2018-01-10
CY2013024I2 (el) 2015-11-04
CA2644530A1 (en) 2007-11-08
PL1999109T3 (pl) 2012-05-31
PT2363392T (pt) 2017-06-15
GT200800201A (es) 2009-08-20
US8840866B2 (en) 2014-09-23
EA200870389A1 (ru) 2009-04-28
AU2007243712B2 (en) 2013-01-10
ES2378785T3 (es) 2012-04-17
FR13C0034I2 (fr) 2014-03-07
SG173338A1 (en) 2011-08-29
SI1999109T1 (sl) 2012-04-30
DK2363392T3 (en) 2017-07-03
LT2363392T (lt) 2017-07-25

Similar Documents

Publication Publication Date Title
KR101376807B1 (ko) 스티릴피리딘 유도체 및 그의 아밀로이드 플라크에 결합 및영상화를 위한 용도
US7250525B2 (en) Stilbene derivatives and their use for binding and imaging amyloid plaques
KR101321619B1 (ko) 스틸벤 유도체, 및 아밀로이드 플라크에 결합 및영상화하기 위한 그의 용도
US20110158907A1 (en) Diphenyl-heteroaryl derivatives and their use for binding and imaging amyloid plaques
CA2672187A1 (en) Acetylene derivatives and their use for binding and imaging amyloid plaques
WO2006078384A2 (en) Stilbene derivatives and their use
AU2012203953A1 (en) Stilbene derivatives and their use for binding and imaging amyloid plaques

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080929

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20111228

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130612

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20131230

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20140314

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20140314

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20170308

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20170308

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20200228

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20200228

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20240228

Start annual number: 11

End annual number: 11